Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply
Resilience and Lilly expand strategic partnership first established in 2023 Investment will significantly increase U.S. production of Lilly’s...
BLOG
Read on
Resilience Announces Relocation of West Coast Headquarters to Ohio and Expansion of Sterile Manufacturing Capabilities
BLUE ASH, Ohio, June 18, 2026 – Resilience, along with Ohio Governor Mike DeWine, JobsOhio, the City of Blue Ash, and REDI Cincinnati, today...
How Early-Phase Companies Can Future-Proof Their Cell Therapies
How Early-Phase Companies Can Future-Proof Their Cell Therapies The following was extracted from a conversation with Eytan Abraham “Q: How should...
Opening of Resilience's West Coast Cell Therapy PAD Center
Resilience is proud to announce the official opening of our West Coast (San Diego, CA) Cell Therapy PAD center. This location will serve as our...
Resilience Enters Into Strategic Collaboration with Labcorp to Accelerate Cell and Gene Therapies
Resilience has entered into a strategic collaboration with Labcorp to establish a joint customer service offering that provides an end-to-end...
Leveraging Partnerships to Achieve Cell Therapy Success
What impact can partnerships have in cell therapy commercialization success? Eytan Abraham at Resilience discusses the need for a modernized...
Cell Therapy – What Does It Take To Become a Mainstream Option
While cell therapies are still a small segment of therapeutics, the landscape is rapidly changing — with over 1,000 ongoing clinical trials and...
